Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ: SPRY )

14.00 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and... 
Via Benzinga
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For November 13, 2024
Via Benzinga
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings
Via Benzinga
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray
Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it. 
Via Investor's Business Daily
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment. 
Via Benzinga
Where ARS Pharmaceuticals Stands With Analysts
Via Benzinga
Analyst Ratings For ARS Pharmaceuticals
Via Benzinga
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned
Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due to limited real-world testing and potential insurance hurdles. 
Via Benzinga
Looking Into ARS Pharmaceuticals's Recent Short Interest
Via Benzinga
SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024
SPRY stock results show that ARS Pharmaceuticals met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Top 5 Health Care Stocks That May Plunge In March
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023
SPRY stock results show that ARS Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
U.S. equities market is rallying, but there are still interesting investments to make, especially for these strong-buy stocks under $10. 
Via InvestorPlace
Allergic Reaction Focused ARS Pharmaceuticals' Lead Candidate Shows Efficacy In Skin Disorder
ARS Pharmaceuticals reports Phase 2 study results for neffy (epinephrine nasal spray) treating chronic spontaneous urticaria. Significant improvements in itch, hives, and erythema scores were observed... 
Via Benzinga
ARS Pharma Readies Data In Response To FDA's Rejection For Its EpiPen Alternative For Severe Allergic Reactions
NAC study results by ARS Pharma comparing neffy (epinephrine nasal spray) to intramuscular injection. Data submission is expected in Q2 2024. 
Via Benzinga
Exposures Product Safety
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results. 
Via Benzinga
Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging
U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Friday. Shares of Synaptics Incorporated (NASDAQ: SYNA) rose sharply on Friday after the company reported better-than-expected... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi... 
Via Benzinga
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
More Than $8M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 40 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
ARS Pharmaceuticals' EpiPen Alternative Delayed US Approval - Two Analysts Offer Differing Views
On Tuesday, The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic... 
Via Benzinga
Exposures Product Safety
What's Going On With ARS Pharmaceuticals Stock Today?
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares are trading higher Thursday. The move marks a rebound in the stock following a recent drop in price. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Gold Moves Higher; Fed Leaves Key Overnight Interest Rate Unchanged
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 200 points on Wednesday. The Dow traded up 0.59% to 34,720.69 while the NASDAQ fell 0.07% to 13,668.37. The S&P 500... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday
The company received a Complete Response Letter from the FDA regarding its lead therapy. 
Via The Motley Fool
Exposures Product Safety
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.